A Phase 1 Dose Escalation, Open-Label Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma
Phase of Trial: Phase I
Latest Information Update: 03 Aug 2018
At a glance
- Drugs Navitoclax (Primary) ; Venetoclax (Primary) ; Dexamethasone; Pegaspargase; Vincristine
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 17 Jun 2018 Preliminary efficacy results (n=3) presented at the 23rd Congress of the European Haematology Association
- 05 Jun 2018 Study design was presented at the 54th Annual Meeting of the American Society of Clinical Oncology. As of Jan 5, 2018, 3 patients were enrolled at dose level one.
- 28 Feb 2018 Planned End Date changed from 12 Jun 2020 to 17 Jun 2020.